Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Disease Areas » Cancer » Agendia's MammaPrint Breast Cancer Risk Test Cost-Effective in Multi-Country Analysis

Agendia's MammaPrint Breast Cancer Risk Test Cost-Effective in Multi-Country Analysis

Aug 26, 2020
|
staff reporter

NEW YORK – MammaPrint, a breast cancer recurrence test sold by Amsterdam-headquartered Agendia, cut healthcare costs in five out of six countries evaluated and was cost-effective in all six, according to an analysis published in the latest issue of the European Journal of Cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

Sponsored by
Agena Bioscience

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
20
Featured Webinar

Crystal Digital PCR for Accurate Chimerism Monitoring after Stem Cell Transplantation

Sponsored by
Stilla

This webinar will discuss a new method that relies on Crystal digital PCR from Stilla Technologies to monitor chimerism in patients after stem cell transplantation, which is a key part of surveillance for impending clinical relapse.

What's Popular?

In Cancer

  1. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  2. Multi-Biomarker Strategies Show Promise in Improving Immunotherapy Response Prediction

    Premium

  3. Ionpath Closes $18M Series B Round

  4. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  5. CRISPR Screen Uncovers Genes That Help Cancer Cells Evade Immune System

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.